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ABSTRACT
Lithium-induced nephrogenic diabetes insipidus (NDI) is accompanied by polyuria, downregulation of
aquaporin 2 (AQP2), and cellular remodeling of the collecting duct (CD). The amiloride-sensitive epithe-
lial sodium channel (ENaC) is a likely candidate for lithium entry. Here, we subjected transgenic mice
lacking ENaC specifically in the CD (knockout [KO] mice) and littermate controls to chronic lithium
treatment. In contrast to control mice, KO mice did not markedly increase their water intake. Further-
more, KO mice did not demonstrate the polyuria and reduction in urine osmolality induced by lithium
treatment in the control mice. Lithium treatment reduced AQP2 protein levels in the cortex/outer
medulla and inner medulla (IM) of control mice but only partially reduced AQP2 levels in the IM of KO
mice. Furthermore, lithium induced expression of H-ATPase in the IM of control mice but not KO mice.
In conclusion, the absence of functional ENaC in the CD protects mice from lithium-induced NDI. These
data support the hypothesis that ENaC-mediated lithium entry into the CD principal cells contributes to
the pathogenesis of lithium-induced NDI.
Nephrogenic diabetes insipidus (NDI) is charac-
terized by the inability of the kidney to concen-
trate urine in response to vasopressin. The dis-
ease is most commonly acquired and often occurs
as an adverse effect in humans subjected to vari-
ous drug treatments (e.g., lithium [Li] therapy).
Li, which is a frequently used drug against manic-
depressive illness, can cause NDI in up to 20 to
40% of patients who take the medication.1 Long-
term Li treatment of rats results in severe down-
regulation of aquaporin 2 (AQP2) and AQP3
protein levels in parallel with extensive poly-
uria.2,3 Moreover, Li causes a remodeling of the
rat kidney collecting duct (CD), which includes a
decreased fraction of principal cells and an in-
creased fraction of intercalated cells.4,5 These del-
eterious effects on the CD are proposed to be
linked to Li accumulation within the principal
cells. Several studies suggested that a likely can-
didate for Li entry is the epithelial sodium chan-
nel (ENaC), which is present in the late distal
convoluted tubule (DCT) cells, the connecting
tubule (CNT) cells, and the CD principal cells.6,7
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ENaC is a heteromultimeric protein
composed of three subunits: , , and .8
ENaC has a higher permeability for Li
than for Na.9,10 Moreover, amiloride, a
specific blocker of ENaC, has been shown
to reduce Li uptake in ENaC-expressing
renal cells11 and to block reabsorption in
the distal nephron of Na-depleted rats.12
Recent studies also showed that amilo-
ride partially prevents development of
Li-NDI in rats11,13 and partially restores the
urine-concentrating ability in patients who
are on Li therapy.14 To provide possibly de-
finitive proof of whether ENaC is involved
in the absorption of Li, we took advantage
of transgenic mice deficient of ENaC spe-
cifically in the CD while leaving ENaC ex-
pression in the late DCT and CNT intact.15
Under salt restriction, whole-cell voltage
clamp of principal cells of the cortical CD
(CCD) showed no detectable ENaC activ-
ity, whereas large amiloride-sensitive cur-
rents were observed in the CCD of con-
trols15 and in the CNT/DCT of both KO
and controls.16 Despite the loss of ENaC
activity in CD, the animals survived well
and were able to maintain Na and potas-
sium (K) balance, even when challenged by
1 week of salt restriction, 23 hours of water
deprivation, or 2 days of K loading.15 We
followed these transgenic mice and their
littermate controls during long-term Li
treatment.
RESULTS
Li Does not Induce Polyuria and Polydipsia in CD-
Specific ENaC KO Mice
Long-term Li treatment induced increased water intake in
the control animals, which was not seen in KO mice (Figure 1A).
As early as day 4 after starting Li treatment, water intake in-
creased in the Li-treated controls, whereas it remained at the
same level throughout the study in the Li-treated KO mice.
After 5 days of Li treatment, there was a highly significant dif-
ference in water intake between the Li-treated controls and the
three other groups that continued for the remaining days of the
diet. In contrast, water intake of the Li-treated KO mice was
not significantly different from the untreated control and KO
mice (Figure 1A). The urine output of the Li-treated controls
was significantly higher compared with the three other groups
(Figure 1B). In parallel, the urine osmolality was significantly
lower in the Li-treated controls compared with the other
groups (Figure 1C). In contrast, there were no significant dif-
ferences in urine output and urine osmolality between the Li-
treatedKOmice and the untreated control andKOmice. Thus,
Li did not cause polyuria and polydipsia in the Li-treated KO
mice that were seen in the Li-treated controls.
The urinary Na and K concentrations were significantly
lower in the Li-treated controls but not in the Li-treated KO
mice (Table 1). The urinary excretion of Na and K, however,
was not changed in the two groups after Li exposure, and there
were no changes in the fractional excretion of Na (FENa)
among the four groups (Table 1). Furthermore, serumconcen-
trations of Na, K, urea, and creatinine and serum osmolality
were unaltered in the two groups after Li exposure (Table 1).
The urinary Li concentration was significantly lower in the
Li-treated controls compared with the Li-treated KO mice,
whereas the urinary Li excretion was not different between the
control and KO groups (Table 1). There were no differences in
Li concentration in the blood between the two Li-treated
groups, and no changes in Li clearance and in fractional excre-
tion of Li were observed (Table 1). There was no significant
difference in food intake between the two groups during the
diet, and no significant changes in body weight were observed
at the end of the diet (Table 1).
Figure 1. Li-treated KO mice do not exhibit higher water intake or urine output or
lower urinary osmolality. (A through C) Water intake (A), urine output (B), and urine
osmolality (C) are measured in Li-treated control mice (n  12; black), Li-treated KO
mice (n  11; white), untreated control mice (n  8; bricks), and untreated KO mice
(n  7; hexagons). After 4 days of Li treatment, water intake is significantly increased
in the Li-treated control mice compared with the Li-treated KO mice; after 5 days, there
is a highly significant difference between the Li-treated control mice and the three
other groups (A). There is no difference in water intake among the Li-treated KO mice,
the untreated control mice, and the untreated KO mice during the entire diet (A). At
the end of the diet, the urine output is significantly increased and the urine osmolality
significantly decreased in the Li-treated control mice compared with the three other
groups (B and C), whereas no differences are observed among the Li-treated KO mice,
the untreated control mice, and the untreated KO mice (B and C). At day 1, n  6, 6,
3, and 3; at day 5 to 6 and 18 to 19, n  9, 8, 8, and 7; at day 8 to 9, n  11, 11, 8,
and 7. *P  0.05; **P  0.01; ***P  0.001.
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Effect of Li Treatment on AQP2 and H-ATPase
Abundance in CD-Specific ENaC KO Mice
It was previously shown that Li treatment of rats causes a dra-
matic decrease in AQP2 abundance.2,4 To investigate whether
the effect was abolished in the Li-treated KO mice, we per-
formed Western blotting of samples from cortex/outer me-
dulla (OM) and inner medulla (IM; Figure 2). Consistent with
the previous results, long-termLi treatment resulted in a severe
and significant downregulation of AQP2 in both IM (Figure
2A) and cortex/OM (Figure 2B). In the cortex/OM of Li-
treated KO mice, AQP2 was significantly higher compared
with the Li-treated controls, and no significant difference was
observed when compared with the untreated KO mice. Thus,
Li treatment did not affect total cortical and outer medullary
AQP2 expression in the KO mice. In IM, AQP2 abundance was
higher in the Li-treated KO mice compared with the Li-treated
controls, although not statistically significant. A significantly
lower AQP2 expression was seen in the Li-treated KO mice
compared with the untreated KO mice. Thus, Li treatment
seems to have some effect on AQP2 expression in the IM of KO
mice.
Westernblot analysis further showednosignificantdifferences
Table 1. Urinary and blood measurements from control and KO mice on a normal diet or a Li diet
Parameter
Li Diet Normal Diet
Controls KO Mice Controls KO Mice
Body weight, % 99.0  2.2a 104.2  1.7 107.4  2.3 105.8  1.1
(n  12) (n  11) (n  8) (n  7)
Food intake, g/g body wt 0.25  0.03 0.22  0.02 0.26  0.03 0.24  0.03
(n  12) (n  11) (n  8) (n  7)
Serum Na, mM 149.7  0.8 151.4  1.0 147.3  0.7 147.0  1.0
(n  6) (n  5) (n  3) (n  3)
Serum K, mM 4.3  0.2 4.4 4.2  0.4 4.5
(n  6) (n  2) (n  3) (n  1)
Serum osmolality, mosmol/kgH2O 345  3 334  8 341 344  4
(n  6) (n  3) (n  2) (n  3)
Serum urea, mM 7.7  0.4 7.6 8.2  0.6 7.4
(n  6) (n  2) (n  3) (n  1)
Serum creatinine, M 27.0  1.4 27.0  2.2 28.0  1.0 27.0  1.1
(n  9) (n  8) (n  6) (n  6)
Plasma/serum Li, mM 0.61  0.16 0.38  0.07 0.75  0.04  103 0.84  0.06  103
(n  7) (n  8) (n  3) (n  3)
Urinary Na, mmol/24 h 0.16  0.03 0.15  0.03 0.13  0.02 0.14  0.01
(n  11) (n  11) (n  7) (n  7)
Urinary Na, mM 23  4b 97  13 91  13 108  20
(n  11) (n  11) (n  7) (n  7)
FENa, % 0.47  0.06 0.97  0.19 0.77  0.18 1.04  0.22
(n  5) (n  5) (n  3) (n  3)
Urinary K, mmol/24 h 0.54  0.07 0.48  0.07 0.40  0.03 0.46  0.03
(n  11) (n  11) (n  7) (n  7)
U-K, mM 79  16b 328  50 324  70 349  62
(n  11) (n  11) (n  7) (n  7)
C-creatinine, l/min per g 9.7  2.4 8.3  3.7 6.0  1.5 7.7  2.3
(n  9) (n  8) (n  6) (n  6)
Urinary creatinine, M 1819  541 4260  732 3577  500 4207  935
(n  12) (n  11) (n  7) (n  7)
Urinary Li, mmol/24 h 0.08  0.01 0.05  0.01 0.20  0.02  103 0.17  0.005  103
(n  11) (n  12) (n  3) (n  3)
Urinary Li, mM 13.4  2.5c 35.5  6.1 93.0  25.0  103 105.0  15.0  103
(n  11) (n  12) (n  3) (n  3)
Li clearance, l/min per g 5.2  0.9 4.8  1.0 6.2  0.8 6.3  0.8
(n  7) (n  3) (n  3) (n  3)
FELi, % 70  23 197  105 69  1 51  10
(n  7) (n  8) (n  3) (n  3)
All measurements are from day 24 except the body weight, which is measured at day 21. Body weight in percentage is calculated as a fraction of day 0
(beginning of the experiment). FELi, fractional excretion of lithium.
aP  0.05 (controls on Li-diet versus controls on normal diet).
bP  0.01 (controls on a Li-diet versus three other groups).
cP  0.01 (controls on a Li-diet versus KO on a Li-diet).
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in H-ATPase abundance in the cortex/OM between the Li-
treated controls and theother groups (Figure 2C). In contrast, the
H-ATPase expression was significantly increased in the IM of
the Li-treated controls compared with the other three groups
(Figure 2D).Moreover, nodifferences between theLi-treated and
untreated KO mice were observed. Thus, Li treatment did not
cause changes in the expression of H-ATPase in the IM of KO
mice in contrast to the control mice.
Decreased AQP2 Labeling in the CD of Li-Treated
Control Mice Compared with Li-Treated KO Mice
To investigate further theAQP2 labeling inLi-treated control and
Li-treated KO mice, we performed immunolabeling on kidney
sections from these two groups. In the CD of Li-treated KO mice,
a strong AQP2 labeling was seen in IM, inner stripe of OM
(ISOM), andcortex (Figure 3,A throughC),whereas in theCDof
the Li-treated controls, the AQP2 labeling was markedly reduced
Figure 2. Li treatment decreases AQP2 expression in inner medulla but not in cortex of KO mice. (A through D) Western blot and
corresponding densitometric analysis of AQP2 (A and B) and H-ATPase expression (C and D) in cortex/OM (A and C) and IM (B and
D) of untreated control mice (control), untreated CD-specific ENaC KO mice (ENaC KO), Li-treated control mice (Li-control),
and Li-treated CD-specific ENaC KO mice (Li-ENaC KO). In cortex/OM, AQP2 protein is significantly reduced in Li-control compared
with the other three groups, whereas AQP2 levels in the Li-ENaC KO is not different from ENaC KO (A). AQP2 protein in IM is
significantly lower in Li-control compared with the two untreated groups but not compared with Li-ENaC KO (B). The expression of
AQP2 in the IM of Li-ENaC KO is significantly lower compared with ENaC KO (B). No differences in H-ATPase protein are observed
between the Li-control and the other groups in cortex/OM (C). In the IM, H-ATPase is significantly higher in the Li-control compared
with the three other groups, whereas the expression in the Li-ENaC KO is not significantly different from the untreated groups (D). *P
0.05; **P  0.01; ***P  0.001.
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(Figure 3, E through G). Thus, Li did not cause a downregulation
ofAQP2expression in theCDofKOmice. In theCNT, therewere
nomajor changes inAQP2 labeling between the two groups (Fig-
ure 3, D and H), indicating that Li does not affect AQP2 levels in
this segment.
Effect of Li on the Density of H-ATPase–Positive Cells
in Control and KO Mice
Immunohistochemistry revealed a slight increased density
of H-ATPase–positive cells in the proximal part of IM and
in the ISOM of the Li-treated controls compared with the
Li-treated KO mice (Figure 4, A, B, E, and F). Moreover,
H-ATPase–positive cells localized next to each other were
seen in the Li-treated controls. In the CCD of the Li-treated
control mice, H-ATPase–positive cells were only occa-
sionally localized next to each other, and, in general, no
major changes in the density of H-ATPase–positive cells
were observed in this segment between the two groups (Fig-
ure 4, C and G). In the CNT and DCT, the density of H-
ATPase–positive cells was not different (Figure 4, D and H).
Cellular counting of H-ATPase–positive cells in the CNT
and DCT revealed no significant changes in the fraction of
H-ATPase–positive cells between the two groups (36.0 
1.4% in control versus 37.0  1.0% in KO; n  3 in each
group; NS). Moreover, multiple H-ATPase–positive cells
next to each other were not observed in these segments.
Thus, Li causes a slight increased density of intercalated cells
in the IM and ISOM of control mice but not in KO mice.
Figure 4. No increase in H-ATPase–positive cells in Li-treated
KO mice compared with Li-treated control mice. (A through H)
Immunohistochemistry using whole kidney sections from Li-
treated CD-specific ENaC KO mice (A through D) and Li-treated
control mice (E through H). Sections were incubated with anti–
H-ATPase antibody. The density of H-ATPase–positive cells
was slightly increased in the IM and ISOM of the Li-treated control
mice (E and F) compared with the Li-treated CD-specific ENaC
KO mice (A and B). In the CCD (C and G) and in the CNT (D
through H), there were no major changes in the density of H-
ATPase–positive cells.
Figure 3. Decreased AQP2 labeling in the CD of Li-treated
control mice compared with Li-treated KO mice. (A through H)
Immunohistochemistry using whole kidney sections from Li-
treated CD-specific ENaC KO mice (A through D) and Li-
treated control mice (E through H). Sections are incubated with
anti-AQP2 antibody. In the IM (A and E), ISOM (B and F), and
the CCD (C and G), AQP2 labeling is markedly reduced in the
Li-treated control mice (E through G) compared with the Li-
treated CD-specific ENaC KO mice (A through C). In the CNT,
there are no changes in AQP2 labeling between the two
groups (D and H).
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Moreover, Li does not seem to have an effect on the density
of intercalated cells in the DCT/CNT.
DISCUSSION
In this study, we show that the absence of functional ENaC in
the CD protects mice from developing Li-induced NDI. The
data provide genetic evidence that ENaC is involved in Li entry
into CD principal cells and thus plays a crucial role in the
pathogenesis of Li-induced NDI. Interestingly, the Li-treated
KO mice did not show signs of NDI, suggesting that the CNT is
able to escape the Li toxicity.
CD-Specific ENaC KO Mice Are Protected from
Development of NDI
In control mice, Li treatment caused severe polyuria, low urine
osmolality, and high water intake, consistent with an impair-
ment of urine concentration and thus NDI.2–4,17 In contrast, Li
did not have an effect on the urine-concentrating ability in
mice that lack ENaC in the CD. Our results are consistent
with a recent rat study in which co-treatment with Li and
amiloride attenuated the Li-NDI11,13 and with the fact that
amiloride administration ameliorates polyuria in patients who
are on long-term Li treatment.18 Furthermore, amiloride pre-
vents Li-induced AQP2 downregulation in mCCDc11 cells.11
We also previously used Li protection as a positive control for
experiments dealing with the role of ENaC in thiazolidinedi-
one-induced fluid retention.19
The higher AQP2 expression in the CD of the Li-treated KO
mice compared with the Li-treated controls is consistent with
the absence of a urine-concentrating defect in the CD of the
KO mice. However, Western blot analysis showed that Li did
have an effect on AQP2 levels in IM of the KO mice as seen by
a significantly lower AQP2 abundance in the Li-treated KO
mice compared with the untreated KO mice. This suggests that
the Li effect onAQP2 levels in the innermedullaryCD (IMCD)
principal cells is not only via an ENaC-mediated entry. Simul-
taneous administration of amiloride and Li to rats has also
been shown not to restore AQP2 levels fully in the IM.11 This
effect may be mediated by prostaglandin E2 (PGE2) because Li
increases cyclooxygenase 2 expression in and PGE2 release
from medullary interstitial cells,20 and it is known that PGE2
can inhibit the effect of vasopressin on water permeability in
the CD.21,22 The decreased AQP2 expression is likely not re-
lated to a decrease in interstitial osmolality because furo-
semide-induced changes in medullary tonicity did not affect
AQP2 levels in rat IM.23 Finally we cannot exclude that some
residual ENaC activity remains in the IM of the KO mice,19 but
this is unlikely to play a physiologically role. The AQP2 down-
regulation in the IMCD was not correlated with changes in
urine output and osmolality in the KO mice. Thus, the water
reabsorption ability did not seem to be impaired. A possibility
is that Li did not affect AQP2 trafficking and that a substantial
amount of AQP2 remained in the apical plasma membrane to
sustain water reabsorption. We previously showed that al-
though cytoplasmic AQP2 is markedly reduced in rat IM after
long-term Li treatment, some AQP2 still remains in the apical
membrane.4
Li administration was associated with a slightly higher den-
sity of intercalated cells (H-ATPase–positive cells) in the IM
and ISOM of the control mice. The increased density of inter-
calated cells was less pronounced, however, compared with
previous studies of rats.4,11,17 The phenomenon was not seen in
KO mice, showing that Li had no effect on the intercalated cells
in these mice. Thus, Li-induced changes of the intercalated
cells require the action of Li on the principal cells.
Western blotting also revealed an upregulation of H-AT-
Pase protein levels in the IM of the Li-treated control mice as
shown in other studies of rats and is likely due to an increase in
the density of intercalated cells.11,17 We did not observe
changes in H-ATPase abundance in OM/cortex in contrast to
that previously shown in Li-treated rats,11,17 suggesting that the
effect of Li on the intercalated cells in mice is not as dramatic as
in rats.
There was no significant change in plasma Li concentration
between the Li-treated groups, and the plasma Li concentra-
tion of 0.6 mM in the Li-treated control mice corresponds to
studies of rats using the same protocol.3
ENaC-Mediated Li Entry
Under normal conditions (i.e., inNa-replete conditions), renal
Li clearance is used as a measurement of tubular fluid delivery
from the proximal tubule. The Li clearance technique assumes
that transcellular transport of Li does not occur in the distal
tubule and the CD. Previous studies have shown that amiloride-
sensitive Li reabsorption takes place only in the distal nephron
during conditions with Na depletion (low-Na diet).12,24 In this
study, we showed that Li-treated mice receiving a normal Na-
containing diet develop NDI and that the absence of ENaC in
the CD prevents the development of NDI. Thus, we show that
ENaC-mediated Li reabsorption does occur in the CD in mice
on a normal-salt diet.
Li treatment is known to be associated with natriuresis, and
experiments with rats using the same Li protocol as in this
study (with the same Na intake in Li-treated and control rats)
have shown that the rate of urinary Na excretion is increased in
Li-treated animals compared with controls.3 In this study, we
did not observe a difference in urinary Na excretion among the
four groups. In a study by Nielsen et al.,25 rats that were on a Li
diet and consumed the same amount of Na as the controls also
had no differences in urinary Na excretion rates, but these rats
had a marked increase in the FENa. However, no differences
in FENa were observed in that study either. Thus, there may
be differences in the Li-induced Na handling in mice and rats.
Li Escape in the CNT
Mice with ENaC inactivated in the CD did not respond on the
Li treatment, suggesting that the CNT is able to escape the
deleterious effects of Li. This is despite that the CNT cells con-
6
ht
tp
://
do
c.
re
ro
.c
h
tain ENaC and therefore should be expected to respond to Li
exposure. The CNT exhibits the same components for water
transport as the CD. AQP2 is expressed in both the CNT and
the CD, although the abundance is lower along the CNT.26,27
Vasopressin-mediated regulation of AQP2 expression and
trafficking occurs in rat CNT, and in mouse and rat, the V2
receptor is equally expressed in the CNT and the CCD.27,28
Vasopressin also increases adenylate cyclase activity in rat
CNT.29
In our study, we did not observe differences in AQP2
levels in the CNT of the Li-treated control and KO mice, and
the density of intercalated cells did not seem to be increased
in the two groups. Moreover, AQP2 protein levels in OM/
cortex were decreased only in the Li-treated control mice
and not in the Li-treated KO mice. Consistently, Li causes
AQP2 downregulation mainly in the CCD and to a lesser
extent in CNT of rats.30
Differences in ENaC expression between CNT and CCD
were observed in rats subjected to Li diet with fixed Na intake
(but not with free access to Na).25 In these animals, - and
ENaC downregulation was observed in CCD and outer med-
ullaryCDbut not inCNT. In contrast, increased apical labeling
of all three ENaC subunits was observed in this segment. This
was explained by possible compensatory mechanisms occur-
ring in CNT to limit the renal Na loss observed in these ani-
mals.25
The difference in Li sensitivity between theCNTand theCD
could be explained by differences in Li delivery to the CNT and
the CD, resulting in differences in the luminal Li concentration
along the CNT and the CD. It is also possible that the Li intra-
cellular concentration rises to toxic levels only in the CD as a
result of a different exit pathway for Li through either the ba-
solateral or the apical plasma membrane in the CNT cells and
CDprincipal cells. Yet another possibility is that the expression
of or the sensitivity to an intracellular target for Li is different in
the CNT and the CD. A potential intracellular target for Li is
glycogen synthase kinase 3 (GSK3). Li has been shown to
inhibit GSK3 activity in the kidney,20 and proteomic studies of
IMCD isolated fromLi-treated rats revealed anupregulation of
the phosphorylated inactive form of GSK3.31 Moreover, an
impaired response to vasopressin was recently shown in CD-
specific GSK3KO mice, suggesting a potential important role
of GSK3 in the vasopressin-mediated water reabsorption.32 A
recent study showed equal expression of the GSK3 transcript
in mouse DCT/CNT and CD.33 However, a potential different
sensitivity, for example, to phosphorylation and thus activity
of the GSK3 protein may exist in the two segments.
CONCISE METHODS
Experimental Protocols
Li chloride was solubilized in water, and the solution was added to
food to yield a Li concentration of 40 mmol/kg dry food as described
previously.3 CD-specific ENaC KO mice (Scnn1alox/lox//HoxB7:
Cre) and the corresponding control mice (Scnn1alox/lox) (2 to 4 and
12 months old) were given a Li-containing diet for 24 to 25 days. In
parallel, CD-specific ENaC KO mice and control mice were given a
normal diet for 24 days. All mice were placed in individual conven-
tional cages, and water intake was measured daily. From day 22 to day
24 of the experiment, all mice were placed in metabolic cages to mea-
sure urine output and osmolality. For the entire experiment, mice had
free access to food and water. At the end of the experiment, blood was
collected from the eye or from the aorta. The experiment was per-
formed three times, and data were pooled.
Urine and Plasma Analysis
Osmolarity and Na and K concentration were analyzed at the Labo-
ratoire Central de Chimie Clinique, Centre Hospitalier Universitaire
Vaudoise (CHUV), Switzerland, or at theDepartment of Clinical Bio-
chemistry, Skejby University Hospital, Denmark. Li concentration
was measured at the Service of Nephrology, CHUV, Switzerland, or at
the Department of Anatomy, Aarhus University, Denmark.
Western Blot Analysis
The kidneyswere dissected into cortex/OMand IMand homogenized
in dissecting buffer as described previously.4 The homogenates were
centrifuged for 15 minutes at 4°C. The total protein concentration
was measured (Pierce BCA protein assay reagent kit; Pierce, Rock-
ford, IL). For confirmation of equal loading of protein, an initial gel
was stained with Coomassie Brilliant blue. SDS-PAGE was performed
on 12.5% polyacrylamide gels (Pierce). After transfer of proteins by
electroelution to nitrocellulose membranes, blots were blocked with
5% milk in PBS-T (80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM
NaCl, and 0.1% Tween 20 [pH 7.5]) for 1 hour and incubated with
anti-AQP2 antibody (7661 AP, 1:1000) or anti-H-ATPase (7659 AP,
1:1000).5 The labeling was visualized with a peroxidase-conjugated
secondary antibody using an enhanced chemiluminescence system
(Amersham Pharmacia Biotech, Buckinghamshire, UK). The labeling
density was quantified using Quantity One software (Bio Rad Labo-
ratories Ltd., Hertfordshire, UK).
Immunohistochemistry
Kidneys from Li-treated KO mice (n 3) and Li-treated control mice
(n 3) were fixed by intravascular perfusion with 3% paraformalde-
hyde in 0.1 M phosphate buffer and subjected to paraffin embedding
and sectioning (2-m-thick sections). Sections were incubated over-
night at 4°C with rabbit polyclonal AQP2 antibody (7661AP, 1:6000
dilution) or rabbit polyclonal H-ATPase antibody (H7659AP,
1:1000 and 1:2000 dilution),5 followed by incubation with horserad-
ish peroxidase–conjugated goat anti-rabbit secondary antibody. La-
beling was visualized using 3,3-diaminobenzidine staining.4
Quantification of H-ATPase–Positive Cells in CNT/
DCT
Cellular counting was performed on kidney sections from Li-
treated KO and Li-treated control mice labeled with H-ATPase
antibody. Counting was performed on electronic images taken
with a 25 objective. The number of H-ATPase–positive and
–negative cells with a distinct nucleus was counted in the CNT and
7
ht
tp
://
do
c.
re
ro
.c
h
the DCT of Li-treated KO mice (1751 cells, n  3) and in the
CNT/DCT of Li-treated control mice (1732 cells, n  3). The
fraction of H-ATPase–positive cells was calculated from the
number of H-ATPase–positive cells divided by the total number
of cells counted for each animal.
Statistical Analysis
Results are presented as means  SEM. Data were analyzed by
one-way ANOVA and unpaired t test. P  0.05 was considered
statistically significant.
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